Prolonged treatment of HCC cells with class I PI3K inhibitors promotes the expansion of liver CSCs, partially by activating the SGK3/ GSK3β/β-catenin signalling pathway (Fig. 7c). Here, PIK3CA is linked to hepatocellular carcinoma.